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Experiment Gamma-CCB at the Cyclotron Centre Bronowice focuses
on investigation of gamma emission in experimental modelling of hadron
therapy, searching for manifestation of the Bragg peak in gamma spectra.
Experimental program comprises a series of measurements for different en-
ergies of the beam accelerated in the cyclotron Proteus C-235, as well as
for several phantom materials. The paper reports on the results of the
first measurements performed at 70 MeV proton beam energy and for two
target materials: graphite and polymethyl methacrylate PMMA. Two dif-
ferent experimental techniques were tested, resulting in differential gamma
spectra or spectra integrated over whole proton penetration path in a phan-
tom. Strong correlation of the intensity of the carbon and oxygen excitation
lines with the Bragg peak position has been observed in both types of mea-





Proton and carbon ion therapy has become a well recognised clinical
technique for cancer treatment (for review, see [1–4]). Although well estab-
lished in clinical practice, hadron therapy still needs detailed studies in some
aspects. One of the urgent issues, indicated by the 2014 NuPECC report
Nuclear Physics for Medicine [5], is a precise on-line determination of the
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ion range in the patient tissue. Currently reached uncertainty of that range
reaches 4.6% + 1.2 mm [6], thus new tools for quality assurance are sought
after. They would enable to fully benefit from the very well defined ion
depth dose profile. Here, Ref. [5] lists prompt gamma (PG) imaging among
most promising options.
Although commonly used simulation engines describe reasonably well the
observed differential distributions of neutrons and charged particles, large
discrepancies were found for the data for γ production in carbon-ion ther-
apy [7]. This calls for an extension of the scarce experimental data base.
The first experiments demonstrating the correlation between prompt γ in-
tensity and the proton range in material were performed only recently [8, 9].
Those studies were extended to carbon ion therapy [10]. These results allow
to expect that PG emission may be used for in-beam single photon emis-
sion tomography. The project, currently conducted at the Cyclotron Centre
Bronowice, aims to measure with high precision the correlation between the
depth of penetration of the beam in phantoms and the spectral and angular
distribution of the emitted γ radiation. Such data will be of great impor-
tance for construction of a new type of a detection system for monitoring of
the delivered dose distribution during radiotherapy.
2. Experimental setup
So far, the group performed two pilot measurements to investigate ex-
perimental conditions at the new Cyclotron Centre Bronowice, which is a
part of IFJ PAN in Cracow [11]. The measurements were conducted using
the 70 MeV proton beam delivered by the Proteus C-235 cyclotron. The
Beam Current Monitor (BCM) in form of a pair of telescopes made of plas-
tic scintillators was used. The telescopes, located about 3 m from the Ti
exit window of the beam pipe registered protons scattered on that window,
thus enabling relative beam intensity monitoring independently on the tar-
get thickness. The proton beam impinged onto one of the two phantoms
(graphite or polymethyl methacrylate PMMA), simulating realistic condi-
tions reached during patient treatment. The two materials were used for
comparison, since also various human tissues differ significantly in their ele-
mental composition. Two versions of target setup were tested, one of them
enabling an integrated gamma emission study, the other a differential mea-
surement (in Fig. 1 exploited simultaneously by the two detectors). The tar-
get thickness was modified remotely from the control room, which allowed
to optimise the measurement time and ensured stability of experimental
conditions over the whole measurement series (a measurement series means
here a set of γ spectra collected for a chosen phantom material at one an-
gle, with target thickness varying from well below to a few millimetres more
than the expected proton range in the material). The γ rays were detected
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using two detection modules, each consisting of a HPGe detector and an
anti-Compton veto made of scintillators. The detectors were mounted on
movable platforms, allowing measurements at different angles.
Fig. 1. Detection setup enabling simultaneous measurements of gamma spectra.
1 — beam pipe, 2 — Ti exit window, 3 and 4 — wedges forming the thick target
setup, 5 — thin target, 6 — lead shielding, 7 — expected Bragg peak position,
8 and 9 — HPGe detectors. Detector 8 registers gamma spectrum integrated over
the whole beam penetration path in the thick target, while detector 9 registers a
differential spectrum.
3. Preliminary results
The very first analysis of the data collected so far focused on the signals
of the transition in carbon 12C4.44→g.s. and in oxygen 16O6.13→g.s., as those
elements are present in the human tissue. Examples of preliminary results
obtained for θLAB = 90◦ for the PMMA phantom are presented in Fig. 2.
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Fig. 2. Left: intensity of the 12C4.44→g.s. versus phantom thickness. Two graphs
represent two measurement series: with the thick target setup (squares/blue) and
thin slice target setup (stars/red). Right: analogous data for the 16O6.13→g.s.
transition. (Preliminary results.)
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In the left pad, intensity of the 12C4.44→g.s. is presented as a function
of target thickness. Squares (blue) represent the integrated measurement
series, while stars (red) depict differential results obtained with the thin slice
target setup. The spectra have been normalised using the BCM count. In the
right pad, the same information is plotted for the 16O6.13→g.s. transition.
Error bars represent statistical uncertainties. Strong correlation with the
Bragg peak position (depicted with the black line) is clearly visible as a
build-up of a plateau in the thick target setup data or a steep fall-off for
the differential data. Moreover, the feature is present for both investigated
phantom materials. This correlation proves that the proposed method has
large potential. In the further course of analysis, the continuum part of the
gamma spectrum will be analysed and parametrised as well.
4. Outlook
It is planned to continue the experimental program with systematic mea-
surements for different γ emission angles as well as other target materials
(e.g. polyoxymethylene POM) and higher beam energies. This will allow to
optimise working conditions for new single photon tomographs, which will
be designed and built in the future.
The project Investigation of gamma emission in experimental modelling
of hadron therapy is carried out within the POMOST programme of the
Foundation for Polish Science, co-financed from the European Union under
the European Regional Development Fund.
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